COMPASS Pathways (CMPS)
COMPASS Pathways (CMPS) Stock Price, Analysis & Data
| Bid | 10.32 |
| Market Cap | 1.95B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -394.19M |
| Beta | n/a |
| EPS (ttm) | -3.79 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.82 |
| P/B (ttm) | 22.58 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 17.66 |
| Volume | 2,351,950 |
| Avg. Volume (20D) | 4,063,743 |
| Open | 13.78 |
| Previous Close | 13.38 |
| Day's Range | 13.65 - 14.59 |
| 52-Week Range | 3.97 - 15.40 |
| Analyst | Strong Buy |
| Price Target | 21 (49.25%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CMPS
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to...
Financial Performance
In 2025, COMPASS Pathways's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -287.86M, an increase of 85.57%.
Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for CMPS stock is "Strong Buy". The 12-month stock price forecast is 21, which is upside of 49.25% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
